Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5‑HT3 receptor antagonist presented as an oral tablet for oral administration. It is used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting caused by cytotoxic chemotherapy. - Postoperative nausea and vomiting: helps prevent and treat nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: alleviates nausea and vomiting resulting from radiotherapy.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are frequently reported. - Dizziness: transient light‑headedness can be experienced.

Serious or Rare Side Effects: - QT prolongation: may lead to cardiac arrhythmias, especially in patients with electrolyte disturbances. - Severe allergic reaction: anaphylaxis or angioedema can develop. - Serotonin syndrome: rare but possible when combined with other serotonergic agents.

Ondansetron should be used with caution in patients with specific risk factors. - Cardiac assessment: evaluate baseline ECG in patients with known heart disease. - Electrolyte monitoring: correct hypokalemia, hypomagnesemia, or hypocalcemia before use. - Hepatic impairment: consider dose adjustment in moderate to severe liver dysfunction. - Concomitant QT‑prolonging drugs: avoid or monitor closely when used together. - Pregnancy and lactation: weigh benefits against potential risks. - Store at room temperature: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medications that affect cardiac rhythm or serotonergic pathways. Major Interactions (Avoid): - Apomorphine: can cause severe hypotension and loss of consciousness. - Other 5‑HT3 antagonists: may increase risk of QT prolongation. - Drugs that prolong QT (e.g., quinidine, amiodarone): heightened arrhythmia risk. - Carbamazepine: induces metabolism, reducing ondansetron efficacy. Moderate Interactions (Monitor Closely): - Dexamethasone: may enhance anti‑emetic effect, monitor for additive side effects. - Serotonergic agents (SSRIs, SNRIs, tramadol): increase risk of serotonin syndrome. - Anticholinergic anti‑emetics: may alter overall anti‑emetic profile.